Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes

Transfusion

Volumn 54, Issue 3, 2014, Pages 681-690

  Michelis, Fotios V ^a   Branch, Donald R ^a   Scovell, Iain ^a   Bloch, Evgenia ^a   Pendergrast, Jacob ^a   Lipton, Jeffrey H ^a   Cserti Gazdewich, Christine M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIBODY; GAMMA INTERFERON; HEMOGLOBIN; HOST FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANGINA PECTORIS; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; BONE MARROW TRANSPLANTATION; CASE REPORT; CHIMERA; CONTROLLED STUDY; DYSPNEA; ERYTHROCYTE; ERYTHROPHAGOCYTOSIS; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEMOGLOBINURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN CELL; INFLAMMATION; MIDDLE AGED; MONONUCLEAR PHAGOCYTE; MYOCARDIAL PERFUSION IMAGING; OPSONIZATION; SEROLOGY; SINUS TACHYCARDIA;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; FEMALE; HEMOLYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MIDDLE AGED; PHAGOCYTES;

EID: 84896047390     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12329     Document Type: Article

References (42)

1. Durandy A, Wahn V, Petteway S, Gelfand EW,. Immunoglobulin replacement therapy in primary antibody deficiency diseases-maximizing success. Int Arch Allergy Immunol 2005; 136: 217-229.
2. Gurcan HM, Ahmed AR,. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007; 41: 812-823.
3. Berard R, Whittemore B, Scuccimarri R,. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J 2012; 10: 10.
4. Jolles S, Sewell WA, Misbah SA,. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142: 1-11.
5. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP,. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-1231.
6. Gelfand EW,. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367: 2015-2025.
7. Pierce LR, Jain N,. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17: 241-251.
8. Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A,. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48: 1598-1601.
9. Thorpe SJ, Fox BJ, Dolman CD, Lawrence J, Thorpe R,. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang 2003; 85: 80-84.
10. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R,. Side effects of intravenous immunoglobulins in neurological autoimmune disorders-a prospective study. J Neurol 2003; 250: 818-821.
11. Morgan S, Sorensen P, Vercellotti G, Zantek ND,. Haemolysis after treatment with intravenous immunoglobulin due to anti-A. Transfus Med 2011; 21: 267-270.
12. Coghill J, Comeau T, Shea T, Braddy L, Bandarenko N, Afenyi-Annan A, Harvey D,. Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG). Biol Blood Marrow Transplant 2006; 12: 786-788.
13. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM,. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120: 926-928.
14. Pintova S, Bhardwaj AS, Aledort LM,. IVIG-a hemolytic culprit. N Engl J Med 2012; 367: 974-976.
15. Wilson JR, Bhoopalam H, Fisher M,. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve 1997; 20: 1142-1145.
16. Egli A, Bucher C, Dumoulin A, Stern M, Buser A, Bubendorf L, Gregor M, Servida P, Sommer G, Bremerich J, Gratwohl A, Khanna N, Widmer AF, Battegay M, Tamm M, Hirsch HH, Halter JP,. Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation. Infection 2012; 40: 677-684.
17. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E,. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001; 27: 877-881.
18. Lee SJ, Churchill WH, Konugres A, Gilliland DG, Antin JH,. Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation- treatment with anti-D immunoglobulin. Bone Marrow Transplant 1997; 19: 173-174.
19. Taylor E,. Intravenous immune globulin (IVIG): hemolytic reactions. Can Adverse React Newslett 2009; 19: 1-2.
20. Canadian Blood Services. IVIG-associated hemolysis. Customer Letter #2011-34. November 21, 2011. [cited June 26, 2013]. Available from: URL: http://www.bloodservices.ca/CentreApps/Internet/UW-V502-MainEngine.nsf/ resources/CustomerLetters2011/$file/CL2011-34.pdf
21. Roback JD, Grossman BJ, Harris T, Hillyer CD, editors. Technical manual. 17th ed. Bethesda (MD): American Association of Blood Banks; 2011.
22. Rampersad GC, Suck G, Sakac D, Fahim S, Foo A, Denomme GA, Langler RF, Branch DR,. Chemical compounds that target thiol-disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells. Transfusion 2005; 45: 384-393.
23. Schwarz H, Humbel BM,. Correlative light and electron microscopy using immunolabeled resin sections. Methods Mol Biol 2007; 369: 229-256.
24. American Association of Blood Banks. Methods section 2-red cell typing, method 2-8: testing saliva for A, B, H, lea, and leb antigens. In:, Roback JD, Grossman BJ, Harris T, Hillyer CD, editors. Technical manual. Bethesda (MD): American Association of Blood Banks; 2011. p. 881-882.
25. Sutherland DR, Kuek N, Azcona-Olivera J, Anderson T, Acton E, Barth D, Keeney M,. Use of a FLAER-based WBC assay in the primary screening of PNH clones. Am J Clin Pathol 2009; 132: 564-572.
26. Thorpe SJ, Fox B, Sharp G, Heath AB, Behr-Gross ME, Terao E, Virata-Theimer ML, Yu MW,. International collaborative study to establish reference preparations to standardise haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulins by the direct method. Pharmeur Bio Sci Notes 2010; 2010: 39-50.
27. Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J,. Hemolysis after high-dose intravenous Ig. Blood 1993; 82: 3789.
28. Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA,. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4: 1993-1997.
29. Chow S, Salmasi G, Callum JL, Lin Y,. Trimming the fat with an IVIG approval process. Transfus Apher Sci 2012; 46: 349-352.
30. Gordon DJ, Sloan SR, de Jong JL,. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol 2009; 84: 771-772.
31. Rouger P, Juszczak G, Doinel C, Salmon C,. Relationship between I and H antigens. I. A study of the plasma and saliva of a normal population. Transfusion 1980; 20: 536-539.
32. Szulman AE,. The histological distribution of the blood group substances in man as disclosed by immunofluorescence: II. The H antigen and its relation to a and B antigens. J Exp Med 1962; 115: 977-996.
33. Pendergrast JM, Pavenski K, Hannach B,. Does deficiency of plasma A/B substances increase the risk of IVIG-mediated hemolysis? Transfusion 2007; 47: 197A.
34. Fontaine MJ, Mills AM, Weiss S, Hong WJ, Viele M, Goodnough LT,. How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products. Transfusion 2012; 52: 2081-2085.
35. Long M, Kalish LA, Neufeld EJ, Grace RF,. Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. Am J Hematol 2012; 87: 315-317.
36. Del Vecchio GC, Giordano P, Tesse R, Piacente L, Altomare M, De Mattia D,. Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. Blood Transfus 2012; 10: 194-199.
37. Zupanska B, Sokol RJ, Booker DJ, Stamps R,. Erythrocyte autoantibodies, the monocyte monolayer assay and in vivo haemolysis. Br J Haematol 1993; 84: 144-150.
38. Davenport RD,. The role of cytokines in hemolytic transfusion reactions. Immunol Invest 1995; 24: 319-331.
39. Gallagher MT, Branch DR, Mison A, Petz LD,. Evaluation of reticuloendothelial function in autoimmune hemolytic anemia using an in vitro assay of monocyte-macrophage interaction with erythrocytes. Exp Hematol 1983; 11: 82-89.
40. Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H,. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999; 13: 129-135.
41. Liepkalns JS, Hod EA, Stowell SR, Cadwell CM, Spitalnik SL, Zimring JC,. Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcgamma receptors in a murine model. Transfusion 2012; 52: 2631-2645.
42. Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, McCrae KR, Tarantino MD, Bussel JB,. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 2012; 52: 1126-1136; quiz 5.